Lantz Financial LLC Sells 230 Shares of Johnson & Johnson (NYSE:JNJ)

Lantz Financial LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,808 shares of the company’s stock after selling 230 shares during the quarter. Lantz Financial LLC’s holdings in Johnson & Johnson were worth $1,031,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Bath Savings Trust Co boosted its stake in Johnson & Johnson by 6.2% during the second quarter. Bath Savings Trust Co now owns 42,275 shares of the company’s stock worth $5,888,000 after acquiring an additional 2,479 shares in the last quarter. Cox Capital Mgt LLC lifted its stake in shares of Johnson & Johnson by 0.6% in the second quarter. Cox Capital Mgt LLC now owns 19,920 shares of the company’s stock valued at $2,774,000 after buying an additional 113 shares in the last quarter. Baystate Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.3% in the second quarter. Baystate Wealth Management LLC now owns 29,643 shares of the company’s stock valued at $4,131,000 after purchasing an additional 372 shares during the last quarter. Deane Retirement Strategies Inc. raised its holdings in shares of Johnson & Johnson by 0.7% in the second quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock valued at $1,724,000 after purchasing an additional 85 shares during the last quarter. Finally, Rockland Trust Co. raised its holdings in shares of Johnson & Johnson by 1.6% in the second quarter. Rockland Trust Co. now owns 152,532 shares of the company’s stock valued at $21,245,000 after purchasing an additional 2,425 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

NYSE JNJ opened at $128.02 on Tuesday. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The company has a 50-day simple moving average of $130.44 and a 200 day simple moving average of $134.60. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The company has a market capitalization of $337.02 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. The business had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter last year, the company posted $2.05 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

Several brokerages have recently commented on JNJ. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price for the company in a report on Thursday, October 17th. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $156.00 to $158.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Finally, Raymond James lowered their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and an average target price of $151.18.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Asset Allocation

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.